Aug 2026
ICARE-TNBC : Immune checkpoint-associated cardiotoxicity risk evaluation in early-stage triple-negative breast cancer
In patients with early-stage TNBC treated with pembrolizumab, cardiotoxicity was frequent and associated with a significant reduction in overall survival, and larger prospective studies are required to better characterise predictors of cardiotoxicity in this setting.
L. Dib, B. Sibila, C. Regragui et al.
· European Heart Journal, Supp... · 0 citations